glp-1 drugs and thyroid cancer Increased screening may lead to higher risk after initiation GLP-1RA and thyroid cancer: New

Improved memory was observed in ApoE 4, whilst worsening memory performance was identified in ApoE 4 non-carriers

Clinical evidence: key trials and outcomes The kidney-protective potential of SGLT2 inhibitors was first identified in cardiovascular outcome trials, including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus PatientsRemoving Excess Glucose (EMPA-REG OUTCOME) [36], Canagliflozin Cardiovascular Assessment Study (CANVAS) [37], and Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARETIMI 58) [38]

Phentermine is a central nervous system stimulant that suppresses appetite by increasing norepinephrine

Piccoli GF, Mesquita LA, Stein C, Aziz M, Zoldan M, Degobi NAH, et al

Long-term outcomes and risk of pancreatic cancer in intraductal papillary mucinous neoplasms

Another review looked at how well different GLP-1 receptor agonists worked when added to metformin in people with type 2 diabetes